Nucleophosmin expression in renal cell carcinoma and oncocytoma

APMIS

Volumn 120, Issue 3, 2012, Pages 187-194

  Sari, Aysegul ^a   Calli, Aylin ^a   Altinboga, Aysegul Aksoy ^a   Pehlivan, Fatma Seher ^a   Gorgel, Sacit Nuri ^a   Balci, Ugur ^a   Ermete, Murat ^a   Dincel, Cetin ^a   Cakalagaoglu, Fulya ^a  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Immunohistochemistry; Nucleophosmin B23; Oncocytoma; Renal cell carcinoma

Indexed keywords

NUCLEOPHOSMIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOPLASM; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; NUCLEOLUS; ONCOCYTOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE SECTION;

ADENOMA, OXYPHILIC; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MIDDLE AGED; NEOPLASM GRADING; NUCLEAR PROTEINS; PARAFFIN EMBEDDING; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84857110679     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2011.02835.x     Document Type: Article

References (27)

1. Eble JN, Sauter G, Epstein JI, Sesterhenn A. WHO Classification of Tumours: Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press, 2004: 23-24.
2. Amin MB, Tamboli P, Javidan J, Stricker H, de-Peralta Venturina M, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 2002;26:281-91.
3. Huo L, Sugimura J, Tretiakova MS, Patton KT, Gupta R, Popov B, et al. C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas. Hum Pathol 2005;36:262-8.
4. Liu L, Qian J, Singh H, Meiers I, Zhou X, Bostwick DG. Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis. Arch Pathol Lab Med 2007;131:1290-7.
5. Haitel A, Wiener HG, Baethge U, Marberger M, Susani M. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin Cancer Res 2000;6:1840-4.
6. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer 2006;6:493-505.
7. Coutinho-Camillo CM, Lourenco SV, Nishimoto IN, Kowalski LP, Soares FA. Nucleophosmin, p53, and Ki-67 expression patterns on an oral squamous cell carcinoma tissue microarray. Hum Pathol 2010;41:1079-86.
8. Korgaonkar C, Hagen J, Tompkins V, Frazier AA, Allamargot C, Quelle FW, et al. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol Cell Biol 2005;25:1258-71.
9. Tanaka M, Sasaki H, Kino I, Sugimura T, Terada M. Genes preferentially expressed in embryo stomach are predominantly expressed in gastric cancer. Cancer Res 1992;52:3372-7.
10. Nozawa Y, Van Belzen N, Van der Made AC, Dinjens WN, Bosman FT. Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J Pathol 1996;178:48-52.
11. Tsui KH, Cheng AJ, Chang PL, Pan TL, Yung BY. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma. Urology 2004;64:839-44.
12. Subong EN, Shue MJ, Epstein JI, Briggman JV, Chan PK, Partin AW. Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23. Prostate 1999;39:298-304.
13. Onda M, Emi M, Yoshida A, Miyamoto S, Akaishi J, Asaka S, et al. Comprehensive gene expression profiling of anaplastic thyroid cancers with cDNA microarray of 25 344 genes. Endocr Relat Cancer 2004;11:843-54.
14. Zhang Y. The ARF-B23 connection: implications for growth control and cancer treatment. Cell Cycle 2004;3:259-62.
15. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005;106:3733-9.
16. Yun JP, Miao J, Chen GG, Tian QH, Zhang CQ, Xiang J, et al. Increased expression of nucleophosmin/B23 in hepatocellular carcinoma and correlation with clinicopathological parameters. Br J Cancer 2007;96:477-84.
17. Mascaux C, Bex F, Martin B, Burny A, Haller A, Paesmans M, et al. The role of NPM, p14arf and MDM2 in precursors of bronchial squamous cell carcinoma. Eur Respir J 2008;32:678-86.
18. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al. AJCC Cancer Staging Manual. American Joint Committee on Cancer. Manual for Staging of Cancer. Philadelphia: Lippincott-Raven, 2002.
19. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-63.
20. Dagli AF, Aydin S, Karaoglu A, Akpolat N, Ozercan IH, Ozercan MR. Ghrelin expression in normal kidney tissue and renal carcinomas. Pathol Res Pract 2009;205:165-73.
21. Gjerset RA. DNA damage, p14ARF, nucleophosmin (NPM/B23), and cancer. J Mol Histol 2006;37:239-51.
22. Lindstrom MS, Zhang Y. B23 and ARF: friends or foes? Cell Biochem Biophys 2006;46:79-90.
23. Jeong EG, Lee SH, Yoo NJ. Absence of nucleophosmin 1 (NPM1) gene mutations in common solid cancers. APMIS 2007;115:341-6.
24. Yung BY. Oncogenic role of nucleophosmin/B23. Chang Gung Med J 2007;30:285-93.
25. Tsui KH, Juang HH, Lee TH, Chang PL, Chen CL, Yung BY. Association of nucleophosmin/B23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples. Acta Pharmacol Sin 2008;29:364-70.
26. Hager M, Haufe H, Kemmerling R, Mikuz G, Kolbitsch C, Moser PL. PTEN expression in renal cell carcinoma and oncocytoma and prognosis. Pathology 2007;39:482-5.
27. Goteri G, Zizzi A, Sabato S, Costagliola A, Stramazzotti D, Rubini C, et al. Immunostaining for nucleophosmin in bone marrow trephine biopsy specimens in acute myeloid leukemias. Anal Quant Cytol Histol 2010;32:201-6.